MediciNova IncNASDAQ:MNOV
- LAST PRICE2.0289
- TODAY'S CHANGE (%)0.0189 (0.9403%)
- Bid / Lots2.0200/ 1
- Ask / Lots2.0300/ 6
- Open / Previous Close2.0300 / 2.0100
- Day Range
- 52 Week Range
- Volume15,068
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MNOV |
|---|---|---|
| 09:32 ET | 9715 | 2.04 |
| 09:33 ET | 323 | 2.0289 |
Nov 19, 2024
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders, from 9:01AM ET on Tuesday Nov 19, 2024 by Dow Jones
9:01AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 14, 2024
Nov 11, 2024
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis, from 6:00PM ET on Monday Nov 11, 2024 by Dow Jones
6:00PM ET on Monday Nov 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
MediciNova Inc | 98.6M | -9.7x | --- |
Milestone Pharmaceuticals Inc | 98.7M | -2.4x | --- |
Oramed Pharmaceuticals Inc | 95.5M | 23.8x | --- |
Avalo Therapeutics Inc | 99.3M | -0.9x | --- |
Renovaro Inc | 96.9M | -0.8x | --- |
Tiziana Life Sciences Ltd | 101.8M | -5.4x | --- |
Company Information
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.
Contact Information
- Headquarters
- SUITE 650, 4275 EXECUTIVE SQUARELA JOLLA, CA, United States 92037
- Phone
- 858-373-1500
- Fax
- 858-404-0048
Executives
- President, Chief Executive Officer, Director
- Yuichi Iwaki
- Chief Financial Officer
- Jason Kruger
- Chief Medical Officer, Director
- Kazuko Matsuda
- Chief Business Officer
- David Crean
- Independent Director
- Carolyn Beaver
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $98.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 49.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.83 |
EPS | $-0.21 |
Book Value | $1.27 |
P/E Ratio | -9.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
